FDMT
NASDAQ · Biotechnology
4D Molecular Therapeutics In
$8.61
-0.37 (-4.12%)
Open$8.63
Previous Close$8.98
Day High$9.10
Day Low$8.59
52W High$12.34
52W Low$2.24
Volume—
Avg Volume733.5K
Market Cap467.74M
P/E Ratio—
EPS$-3.74
SectorBiotechnology
Analyst Ratings
Strong Buy
17 analysts
Price Target
+145.2% upside
Current
$8.61
$8.61
Target
$21.11
$21.11
$12.84
$21.11 avg
$26.25
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 36.5K | 286.9K | 228.58M |
| Net Income | -155,328,961 | -1,099,890,361 | -57,732,834 |
| Profit Margin | -434,778.4% | -413,039.5% | -25.3% |
| EBITDA | -176,955,528 | -1,322,641,633 | -107,016,126 |
| Free Cash Flow | — | — | -89,291,698 |
| Rev Growth | -87.3% | -87.3% | +10.3% |
| Debt/Equity | — | — | 0.12 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |